This Medudy course is a conference report for physicians on the topic “2025 ASCO GU Genitourinary Cancers Symposium”. Prof. Dr. Axel S. Merseburger's AI avatar summarizes the most important studies of the congress. Each study is presented in short 20-second segments.
The key results of LIBERTAS, a post-hoc analysis of the TITAN study, an analysis comparing cabazitaxel with 177-lutetium-PSMA radioligand therapy, a study on bone-modifying agents in mCRPC patients, current data from the EV-302 update and the final results of the COSMIC-313 study will be presented.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this conference report you will know:
– some of the highlights of ASCO GU 2025
– the most important takeaways from the studies
– the conclusion of the studies
